CSBR - Company ID 0000771856
The table below shows CHAMPIONS ONCOLOGY, INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | $15.23M | $16.56M | $15.04M | $13.99M | $17.04M | $13.49M |
| Cost of revenue | $7.53M | $8.83M | $7.26M | $8.00M | $6.62M | $7.43M |
| Gross profit | - | - | - | - | - | - |
| R&D | $2.34M | $2.27M | $2.62M | $2.08M | $1.72M | $1.69M |
CHAMPIONS ONCOLOGY, INC. reported annual revenue of $59.42M for fiscal year 2026. That is up 4.4% from $56.94M in fiscal 2025. Over the 9 fiscal years shown, annual revenue grew from $20.24M (FY 2018) to $59.42M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $2.67M |
| $2.98M |
| $2.97M |
| $2.57M |
| $2.40M |
| $1.89M |
| Operating income | -$409.00K | -$276.00K | $185.00K | -$527.00K | $4.50M | $732.00K |
| Income tax | $11.00K | $42.00K | $18.00K | $14.00K | $23.00K | $11.00K |
| Net income | -$426.00K | -$279.00K | $268.00K | -$436.00K | $4.50M | $728.00K |
| EPS (diluted) | - | -$0.02 | $0.02 | -$0.03 | $0.31 | $0.05 |